Lasa Supergenerics Limited (BOM:540702)
India · Delayed Price · Currency is INR 10.25
-0.15 (-1.44%)
At close: Aug 1, 2025
Lasa Supergenerics Company Description
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India.
It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, and halquinol, as well as 2,6-diiodo-4-nitrophenol; and other API products.
The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide.
In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
Lasa Supergenerics Limited
| Country | India |
| Founded | 2016 |
| Industry | Medicinal Chemicals and Botanical Products |
| Employees | 77 |
| CEO | Omkar Herlekar |
Contact Details
Address: Plot no. C-4 Ratnagiri, 415722 India | |
| Phone | 91 96 0797 3801 |
| Website | lasalabs.com |
Stock Details
| Ticker Symbol | 540702 |
| Exchange | Bombay Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | INR |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Omkar Herlekar | Chief Executive Officer |
| Varsha Joshi | Chief Financial Officer |